IPO
As initial public offerings and mergers and acquisitions declined in 2022, diagnostics firms found it harder to get funding for R&D and commercialization efforts.
The firm uses epigenetic and genetic information, along with machine learning to determine a patient's risk of cardiovascular disease.
South Korean Biotech Lunit Prices $28M IPO
The company, which is developing artificial intelligence-based technologies for cancer diagnosis and treatment, will float its shares on the KOSDAQ.
In 2021, 19 diagnostic companies went public, but so far in 2022 only two have announced their intentions to go public.
Nineteen companies went public during the year, with two offerings nabbing proceeds of more than $1 billion and two more above $500 million.
Nov 10, 2021
Bluejay Diagnostics Prices $21.6M IPO
Sep 2, 2021
Cue Health Files for IPO for up to $100M
Jul 19, 2021
Sophia Genetics Increases IPO Target to $221M
Jul 14, 2021
Sera Prognostics Goes Public With $75M IPO
Jun 30, 2021
Apr 28, 2021
Mar 12, 2021